“This year’s ASCO marks the fourth in a row where potential practice-changing ENHERTU data will be showcased,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. “With the results ...

"This year’s ASCO marks the fourth in a row where potential practice-changing ENHERTU data will be showcased," said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. "With the results of ...

(Image/Reuters) Northern TK Venture (NTK), a Singapore-based indirect arm of Malaysia’s IHH Healthcare, has raised its damages claims against Japanese pharma firm Daiichi Sankyo Company by ...

IHH Healthcare, supported by Mitsui, has increased its compensation claim against Daiichi Sankyo to $1.3 billion in the Tokyo District Court, related to the Fortis Healthcare acquisition.

Daiichi Sankyo and MSD have announced the first subject dosing in the Phase III Ideate-Esophageal01 trial, assessing the safety and efficacy of ifinatamab deruxtecan (I-DXd) in individuals with ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients ...

Every year, April brings the peak bloom period for cherry blossom trees — and one pharma company is tying its involvement with the springtime ritual to its efforts in the oncology space. Japanese ...

Daiichi Sankyo Company, Limited, a leading Japanese pharma, excels in ADC technology, with flagship product Enhertu driving significant revenue growth and global market leadership. Strong ...

WASHINGTON (7News) — Daiichi Sankyo Inc., an innovative pharmaceutical company's deep ties to the Cherry Blossoms in Washington, DC dates back more than a century to the company's first ...

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1 ...

Daiichi Sankyo is turning to the German city of Heidelberg for help developing antibodies. The Japanese pharma giant is teaming up with independent research institute BioMed X to form a new ...